Skip to content

Mineralys Therapeutics

US · MLYS #2760 by market cap Listed 2023
13.66 -0.50 -3.53%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)
    TipRanks · 2026/8/13
  • Rating change
    Guggenheim Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $48
    Market Newswire · 2026/5/19
  • Rating change
    BofA Securities Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $49
    Market Newswire · 2026/10/12
  • UBS Maintains Mineralys Therapeutics(MLYS.US) With Hold Rating, Maintains Target Price $29
    Market Newswire · 2026/10/12
  • Rating change
    Bank of America Securities Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/8/12
  • Rating change
    A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $40 to $56
    Market Newswire · 2026/8/13
  • A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $17 to $56
    Market Newswire · 2026/11/6
  • Rating change
    UBS Initiates a Hold Rating on Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/10/12
  • Rating change
    LifeSci Capital Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $54
    Market Newswire · 2026/8/12
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Palvella Therapeutics (PVLA) and Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/10/12
  • Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $55
    Market Newswire · 2026/11/6
  • Rating change
    A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $42 to $56
    Market Newswire · 2026/5/8
  • H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $56
    Market Newswire · 2026/11/10
  • Rating change
    Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/10/12
  • UBS Maintains Mineralys Therapeutics(MLYS.US) With Hold Rating, Cuts Target Price to $19
    Market Newswire · 2026/11/6
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), Mineralys Therapeutics, Inc. (MLYS) and ArriVent BioPharma, Inc. (AVBP)
    TipRanks · 2026/6/4
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Legend Biotech (LEGN) and Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/8/12
  • Rating change
    Goldman Sachs Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/6/4
  • Rating change
    UBS Initiates Mineralys Therapeutics(MLYS.US) With Hold Rating, Announces Target Price $29
    Market Newswire · 2026/10/12
  • Rating change
    Mineralys Therapeutics, Inc. (MLYS) Gets a Buy From Wells Fargo
    TipRanks · 2026/8/12
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL), Myriad Genetics (MYGN) and Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/5/8
  • Mineralys Therapeutics (MLYS.US) will release its financial report after the market close on November 4.
    Market Newswire · 2026/10/30
  • H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $56
    Market Newswire · 2026/10/23
  • Rating change
    Analysts Are Bullish on Top Healthcare Stocks: CVS Health (CVS), Mineralys Therapeutics, Inc. (MLYS)
    TipRanks · 2026/5/7
  • Rating change
    TD Cowen Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating
    Market Newswire · 2026/5/7

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Mineralys Therapeutics discussion 0 comments

Add a comment